Advertisement

Tumor-Directed Cellular Immunity in Malignant Melanoma and the Antigens That Evoke It

  • Alistair J. Cochran

Abstract

The stimulus to study host responses in patients with malignant melanoma is provided by the observation that the clinical course of this neoplasm is not as uniformly bad as was previously believed by the medical profession and the informed laity (Solzhenitsyn, 1968). In favorable groups of patients with small superficial tumors [< 0.76 mm by micrometric measurement (Breslow, 1970)], the cure rate may considerably exceed 50%. Even in patients with disease in the regional lymph nodes, between 20 and 36% (Cochran, 1969a; Gallery et al., 1982) will remain tumor-free 5 years after therapeutic lymphadenectomy. Prognosis can be, in fact, quite accurately quantified prospectively (Cochran, 1968; MacKie et al., 1972; Gallery et al., 1982). Some of the variability in prognosis is undoubtedly due to biological characteristics of the primary tumor such as thickness (Breslow, 1970) (which probably correlates with tumor volume and thus tumor-cell number), depth of invasion relative to anatomical landmarks of the skin (Clark, 1967; Cochran, 1969b), histogenetic pattern, mitotic rate, blood vascular or lymphatic invasion (McGovern et al., 1973), and number of regional nodes replaced by tumor (Gallery et al., 1982; Cochran, 1969a). It is highly probable that the manner in which the patient reacts to the developing tumor is also very relevant.

Keywords

Melanoma Patient Bacillus Calmette Guerin Detectable Tumor Purify Protein Derivative Control Donor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andersen, V., Bjerrum, O., and Bendixen, G., 1970, Effect of autologous mammary tumour extracts on human leukocyte migration in vitro, Int. J. Cancer 5: 357.PubMedCrossRefGoogle Scholar
  2. Avis, P., and Lewis, M. E., 1973, Brief communication: Tumor-associated fetal antigens in human tumors, J. Natl. Cancer Inst. 51: 1063.PubMedGoogle Scholar
  3. Baldwin, R. W., and Price, M. R., 1976, Nature and expression of tumor antigens associated with experimental animal and human tumors, Ann. Clin. Biochem. 13 (5): 488.PubMedGoogle Scholar
  4. Breslow, A., 1970, Thickness, cross-sectional area and depth of invasion in the prognosis of cutaneous melanoma, Ann. Surg. 172: 902.PubMedCrossRefGoogle Scholar
  5. Buinauskas, P., Brown E. R., and Cole, W. H., 1965, Inhibiting and enhancing effect of various chemical agents on rat’s resistance to inoculated Walker 25 tumor cells, J. Surg. Res. 5: 538.PubMedCrossRefGoogle Scholar
  6. Burnet, F. M., 1967, Immunological aspects of malignant disease, Lancet 1: 1171.PubMedCrossRefGoogle Scholar
  7. Callery, C., Roe, D., Cochran, A. J., and Morton, D. L., 1982, Natural history of Stage II melanoma, Ann. Surg (in press).Google Scholar
  8. Clark, W. H., 1967, A classification of malignant melanoma in man correlated with histogenesis and biological behavior, in: Advances in Biology of the Skin, Vol. 8 (W. Montagna and F. Hu, eds.), pp. 621, Pergamon Press, Oxford.Google Scholar
  9. Cochran, A. J., 1968, Method for assessment of prognosis in malignant melanoma, Lancet 2: 1062.PubMedCrossRefGoogle Scholar
  10. Cochran, A. J., 1969a, Malignant melanoma: A review of 10 years’ experience in Glasgow, Scotland, Cancer 23: 1190.PubMedCrossRefGoogle Scholar
  11. Cochran, A. J., 1969b, Histology and prognosis in malignant melanoma, J. Pathol. 97:459.CrossRefGoogle Scholar
  12. Cochran, A. J., 1971, Tumor cell migration, Eur. J. Clin. Biol. Res. 16: 44.Google Scholar
  13. Cochran, A. J., 1978, Man, Cancer and Immunity, Academic Press, London, New York, San Francisco.Google Scholar
  14. Cochran, A. J., Diehl, V., and Stjernswärd, J., 1970, Regression of primary malignant melanoma associated with a good prognosis despite metastasis to lymph nodes, Rev. Eur. Etud. Clin. Biol. 15: 969.Google Scholar
  15. Cochran, A. J., Spilg, W. G. S., Mackie, R. M., and Thomas, C. E., 1972a, Postoperative depression of tumordirected cell mediated immunity in patients with malignant disease, Br. Med. J. 3: 67.CrossRefGoogle Scholar
  16. Cochran, A. J., Klein, E., and Kiessling, R., 1972b, The effect of immune factors on the motility of lymphoma cells, J. Natl. Cancer Inst. 48:1657.Google Scholar
  17. Cochran, A. J., Jehn, U. W., and Gothaskar, B. P., 1973, Cell-mediated immunity to malignant melanoma, Pigment Cell 1: 360.Google Scholar
  18. Cochran, A. J., Mackie, R. M., Ross, C. E., Ogg, L. J., and Jackson, A. M., 1976, Leukocyte migration inhibition by sera from melanoma patients, Int. J. Cancer 18: 274.PubMedCrossRefGoogle Scholar
  19. Cochran, A. J., Mackie, R. M., Jackson, A. M. Ogg., L. J., and Ross, C. E., 1977, Immunological changes in cancer patients receiving BCG, Dev. Biol. Standard 38: 441.Google Scholar
  20. Cochran, A. J., Mackie, R. M., Morrison, L. J. A., Jackson, A. M., and Todd, G., 1979, Laboratory studies in the early detection of metastatic malignant melanoma, in: Proceedings of the XII International Cancer Congress, (S. Kumar, ed.), pp. 113–120, Pergamon Press, Oxford.Google Scholar
  21. Cochran, A. J., Todd., G., Hart, D. M., Morrison, L. H. A., and MacKie, R. M., 1982, Patterns of reaction of melanoma patients and control donors, including pregnant women, with melanoma and fetus-derived materials, Int. J. Cancer (in press).Google Scholar
  22. Coggin, J. H., and Anderson, N. G., 1974, Cancer, differentiation and embryonic antigens: Some central problems, Adv. Cancer Res. 19: 105.PubMedCrossRefGoogle Scholar
  23. Culbert, E. J., Cochran, A. J., and Clements, G. B., 1982, Tissue cultured lymphoblastoid cells as indicators of lymphokine generation, Scand. J. Immunol. (in press).Google Scholar
  24. Currie, G. A., Lejeune, F., and Fairley, G. H., 1971, Immunization with irradiated tumor cells and specific cytotoxicity in malignant melanoma, Br. Med. J. 2: 305.PubMedCrossRefGoogle Scholar
  25. D’Angio, G. L., Evans, A., and Everett Koop, C., 1971, Special patterns of widespread neuroblastomas with a favorable prognosis, Lancet 2: 1046.CrossRefGoogle Scholar
  26. Everson, T. C., and Cole, W. H., 1966, Spontaneous Regression of Cancer, W. B. Saunders, Philadelphia.Google Scholar
  27. George, M., and Vaughan, J. H., 1962, In vitro cell migration as a model for delayed hypersensitivity, Proc. Soc. Exp. Biol. Med. 111: 514.PubMedGoogle Scholar
  28. Gershon, R. K., 1974, Regulation of concomitant immunity activation of suppressor cells by tumor excision, in: Immunological Parameters of Host-Tumor Relationships, Vol. III ( D. Weiss, ed.), pp. 198–209, Academic Press, New York and London.Google Scholar
  29. Herberman, R. B., and Holden, H. T., 1979, Natural killer cells as anti-tumor effector cells, J. Natl. Cancer Inst. 62: 441.PubMedGoogle Scholar
  30. Irie, R. F., Irie, K., and Morton, D. L., 1976, A membrane antigen common to human cancer and fetal brain tissue, Cancer Res. 36: 3510.PubMedGoogle Scholar
  31. Irie, R. F., Guiliano, A. E., and Morton, D. L., 1979, Oncofetal antigen (OFA): A tumor-associated fetal antigen immunogenic in man, J. Natl. Cancer Inst. 63: 367.PubMedGoogle Scholar
  32. Jackson, A. M., Vose, B. M., and Cochran, A. J., 1978, Tumor-associated antigens in cystic melanomas, Eur. J. Cancer 14: 543.PubMedGoogle Scholar
  33. MacKie, R. M., Carfrae, D. C., and Cochran, A. J., 1972, The assessment of prognosis in patients with malignant melanoma, Lancet 2: 455.PubMedCrossRefGoogle Scholar
  34. MacKie, R. M., Spilg, W. G. S., Thomas, C. E., Cameron-Mowat, D. E., Grant, R. M., and Cochran, A. J., 1973, A comparison of tumor-directed cell mediated immunity and tumor histology in melanoma patients, Rev. Inst. Pasteur Lyon 6: 281.Google Scholar
  35. McCoy, J. L., Jerome, L. F., Dean, J. H., Perlin, E., Oldham, R. K., Char, D. H., Cohen, M. H., Felix, E. L., and Herberman, R. B., 1975, Inhibition of leukocyte migration by tumor-associated antigens in soluble extracts of human malignant melanoma, J. Natl. Cancer Inst. 55: 19.PubMedGoogle Scholar
  36. McGovern, V. J., Mihm, M. C., Bailly, C., Booth, J. C., Clark, W. H., Cochran, A. J., Hardy, E. G., Hicks, J. D., Levene, A., Lewis, M. G., Little, J. H., and Milton, G. W., 1973, The classification of malignant melanoma and its histologic reporting, Cancer 32: 1446.PubMedCrossRefGoogle Scholar
  37. Morrison, L. J. A., Cochran, A. J., MacKie, R. M., Ross, C. E., Todd, G., and Garland, C. G., 1979, Indirect leukocyte migration assay in patients with malignant melanoma, Int. J. Cancer 24: 11.PubMedCrossRefGoogle Scholar
  38. Morrison, L. J. A., Cochran, A. J., Baird, G. M., Campbell, A. M., and Willoughby, M. L. N., 1982, Tumordirected immunity in human neuroblastoma, Am. J. Pediatr. Hematol. Oncol. (in press).Google Scholar
  39. Munster, A. M., Eurenius, K., Mortensen, R. F., and Mason, A. D., 1972, Ability of splenic lymphocytes from injured rats to induce a graft versus host reaction, Transplantation 14: 106.PubMedCrossRefGoogle Scholar
  40. Nairn, R. C., Guli, E. P. G., Nind, A. P. D., Miller, H. K., Rolland, J. M., and Minty, G. C., 1971, Specific immune response in human skin carcinoma, Br. Med. J. 4: 701.PubMedCrossRefGoogle Scholar
  41. O’Toole, C., Perlmann, P., Unsgaard, B., Moberger, G., and Edsmyr, F., 1972, Cellular immunity to human urinary bladder cancer. H. Effect of surgery and preoperative irradiation, Int. J. Cancer 10: 92.PubMedCrossRefGoogle Scholar
  42. Rocklin, R. E., Remold, H. G., and David, J. R., 1972, Characterization of human migration inhibitory factor (MIF) from antigen-stimulated lymphocytes, Cell. Immunol. 5: 436.PubMedCrossRefGoogle Scholar
  43. Ross, C. E., Cochran, A. J., Hoyle, D. E., Grant, R. M., and Mackie, R. M., 1975, Formalin-fixed tumour cells in the leukocyte migration test, Clin. Exp. Immunol. 22: 126.PubMedGoogle Scholar
  44. Ross, C. E., Cochran, A. J., Jackson, A. M., Mackie, R. M., and Ogg, L. J., 1979, The mechanism of tumor cell induced inhibition of human leukocyte migration, Eur. J. Cancer 15: 995.PubMedGoogle Scholar
  45. Seborg, M., and Bendixen, G., 1967, Human lymphocyte migration as a parameter of hypersensitivity, Acta Med. Scand. 181: 247.Google Scholar
  46. Solzhenitsyn, A. I., 1968, Cancer Ward, Bodley Head, London.Google Scholar
  47. Thomas, L., 1959, Mechanisms involved in tissue damage by the endotoxins of gram-negative bacteria, in:Cellular and Humoral Aspects of the Hypersensitivity State (H. S. Lawrence, ed.), 451–468, Hoeber, New York.Google Scholar
  48. Thor, D. E., Jureziz, R. E., Veach, S. R., Miller, E., and Drays, S., 1968, Cell migration inhibition factor released by antigen from human peripheral lymphocytes, Nature (London) 219: 755.CrossRefGoogle Scholar
  49. Todd, G., Chan, C. W., Cochran, A. J., Kennedy, R., MacKie, R. M., and Morrison, L. J. A., 1980, In vitro reaction of cancer patients and others to bacillus Calmette Guérin, Int. J. Cancer 26: 285.PubMedCrossRefGoogle Scholar
  50. Vose, B. M., and Moudgil, G. C., 1975, Effect of surgery on tumour-directed leukocyte responses, Br. Med. J. 1: 56.PubMedCrossRefGoogle Scholar
  51. Vose, B. M., and Moudgil, G. C., 1976, Postoperative depression of antibody-dependent lymphocyte cytoto icity following minor surgery and anesthesia, Immunology 30: 123.PubMedGoogle Scholar
  52. Wilson, N. I. L., Ross, C. E., MacKie, R. M., and Cochran, A. J., 1979, A study of the immunology of nonmalignant melanocytic lesions, Cancer Immunol. Immunother. 6: 27.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • Alistair J. Cochran
    • 1
  1. 1.Division of Surgical Oncology and Departments of Surgery and PathologyUCLA School of Medicine, University of CaliforniaLos AngelesUSA

Personalised recommendations